Get the Stockscreener App
15.47
2.48%
0.375
After Hours:
15.47
Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News
(ARWR) Pivots Trading Plans and Risk Controls - Stock Traders Daily
RNA Therapies Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approval, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight - The Globe and Mail
First Capital REIT Announces March 2025 Distribution - The Globe and Mail
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by US Bancorp DE - Defense World
Bank of New York Mellon Corp Sells 36,341 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead stock holds Buy rating, $80 target from H.C. Wainwright By Investing.com - Investing.com UK
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - AOL
Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 4.2% drop adds to a year losses - Simply Wall St
Buy Rating for Arrowhead Pharmaceuticals Driven by Promising ARO-C3 Trial Results and Strategic Pipeline Advancements - TipRanks
Arrowhead Pharmaceuticals Stock Dips Despite Promising Study - TipRanks
Mutual of America Capital Management LLC Sells 1,519 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy - BioSpace
Arrowhead Pharmaceuticals Says Study for Complement-Mediated Disease Therapy Shows C3 Reduction in Patients - Marketscreener.com
Arrowhead Pharma Reports Positive Topline Data From Phase 1/2 Study Of ARO-C3 - Nasdaq
Arrowhead Pharmaceuticals Announces Topline Results From Part 2 Of Phase 1/2 Study Of Aro-C3 In Patients With IgA Nephropathy - Marketscreener.com
Arrowhead Clinical Trial: 87% C3 Reduction in IgA Nephropathy Patients - StockTitan
Arrowhead Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Arrowhead Pharmaceuticals CEO sells $5.27 million in stock By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases - Lelezard
Arrowhead Pharmaceuticals Presents Data on Two Clinical-Stage Candidates for Obesity Treatment - Marketscreener.com
Arrowhead advances RNAi obesity treatments in clinical trials - Investing.com
Arrowhead advances RNAi obesity treatments in clinical trials By Investing.com - Investing.com UK
Can These Two RNAi Drugs Revolutionize Obesity Treatment? Arrowhead's Promising Data - StockTitan
Arrowhead Pharmaceuticals CEO sells $5.27 million in stock - Investing.com
Familial Chylomicronemia Syndrome Market to Expand - openPR
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Position Trimmed by Principal Financial Group Inc. - Defense World
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS) - Galveston County Daily News
How Arrowhead's New FCS Resources Could Transform Life for Rare Disease Patients - StockTitan
Rhumbline Advisers Increases Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Objective long/short (ARWR) Report - Stock Traders Daily
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity - The Bakersfield Californian
Can Arrowhead's New Obesity Drug Outperform GLP-1s? Preclinical Data Shows Key Advantage - StockTitan
Van ECK Associates Corp Raises Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Empowered Funds LLC Takes $268,000 Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions (NASDAQ:ARWR) - Seeking Alpha
Fat, not muscle: drugmakers in race for next weight-loss breakthrough - Reuters
Zacks Small Cap Has Pessimistic Outlook of ARWR Q2 Earnings - MarketBeat
Analysts Offer Predictions for ARWR Q2 Earnings - MarketBeat
Arrowhead Pharmaceuticals' SWOT analysis: RNAi pioneer's stock poised for potential breakthrough By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals' SWOT analysis: RNAi pioneer's stock poised for potential breakthrough - Investing.com
Arrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
B. Riley Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat
Guidewire Software set to join S&P MidCap 400; Arrowhead Pharmaceuticals to join S&P SmallCap 600 - MSN
Leerink Partnrs Analysts Raise Earnings Estimates for ARWR - MarketBeat
Yousif Capital Management LLC Lowers Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 5%What's Next? - MarketBeat
Arrowhead and Sarepta close $500 million licensing deal - MSN
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):